Novo Nordisk A/S gets EU approval for blood disorders drug.
NORDIC BUSINESS REPORT-20 February 2004-Novo Nordisk A/S gets EU approval for blood disorders drug(C)1994-2004 M2 COMMUNICATIONS LTD http://www.m2.com
Danish pharmaceutical company Novo Nordisk A/S has received approval from the European Commission for its NovoSeven drug for the treatment of two rare blood disorders.
NovoSeven has been approved for the control of bleeding in patients with factor VII deficiency and also for patients suffering from Glanzmann's thrombasthenia.
NovoSeven is the first genetically engineered or recombinant product that has been licensed to treat these disorders, Novo Nordisk said.
((Comments on this story may be sent to email@example.com))
|Printer friendly Cite/link Email Feedback|
|Publication:||Nordic Business Report|
|Date:||Feb 20, 2004|
|Previous Article:||Securitas signs final agreement to acquire Pengar i Sverige AB.|
|Next Article:||Decline in number of asylum applicants in Norway.|